entertainment -WSS

entertainment

author：leisure time 2025-09-30 01:12:45 - browse：9

Mel Evans/AP

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just over twice Harpoon’s market price entering the week.

The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug. That could come as soon as 2028.

Keytruda, a PD-(L)1 inhibitor, works by turning off a “brake” on T cells, allowing roving immune cells to attack tumors. Harpoon’s pipeline belongs to a new class of cancer drugs designed to grab onto the T cells and tumor cells and bring them together.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： WuXi out of biotech trade group, U.S. and China relations to blame

explore

WSS

How many hemophilia patients actually want gene therapy?

Pediatric cancer treatments threatened by a new FDA policy

As AI in medicine takes off, can 'human in the loop' prevent harm?

Change Healthcare outage fallout shows need for new oversight

Organ aging and disease risk measured by new blood test

Male and female sex labels in research insufficient, scientists say

leisure time

entertainment

focus

Wildfire smoke exposes gaps in outdoor worker protections

John Green on his newest strategy for fighting tuberculosis

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

FDA investigates CAR

Medicare proposal to cover medical devices draws a mixed reaction

Takeda, Janssen join wearable maker to measure scratching

Anesthesiologist group: stop taking Ozempic before surgery

John Green on his newest strategy for fighting tuberculosis

explore

With clinical trial data readouts, here's how to spot spin

Why depression after traumatic brain injury is distinct

How to pay for weight loss drugs and save Medicare

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Amid AI frenzy, a top HHS official's quest to create safeguards

CDC director unscathed in first congressional testimony

hotspot

explore

leisure time

focus